Deep tech and biotech VC investing in pre-IPO companies with focus on Series A
Deep tech and biotech VC investing in pre-IPO companies with focus on Series A
Octave has raised $187.0M across 6 funding rounds.
Key people at Octave.
Octave has raised $187.0M in total across 6 funding rounds.
Key people at Octave.
Octave has raised $187.0M in total across 6 funding rounds.
Octave's investors include Asset Management Ventures, Deerfield Management, Health Velocity Capital, Northpond Ventures, Section 32, Flare Capital Partners, Optum Ventures, American Express Ventures, Bessemer Venture Partners, sequel.
Octave Ventures is a global venture capital firm specializing in deep tech and biotech investments, primarily targeting pre-IPO companies with a focus on Series A and beyond. Their mission centers on partnering with innovative founders to foster growth and advance cutting-edge technologies that have the potential to generate significant returns (8-15x ROI) while pushing technological and medical breakthroughs. Octave invests across multiple stages, from early to growth, supporting companies that develop transformative products in biotech and deep technology sectors, thereby impacting the startup ecosystem by enabling high-potential ventures to scale and succeed globally[1][3][4].
For portfolio companies, Octave typically backs ventures building advanced biotech or deep tech products that address critical scientific or technological challenges. These companies serve specialized markets such as healthcare, diagnostics, therapeutics, or industrial technology, solving problems like disease detection, treatment innovation, or novel computing methods. Many portfolio companies show strong growth momentum, with some progressing to public offerings, reflecting Octave’s ability to identify and nurture startups with scalable, high-impact solutions[3][5].
Octave Ventures was founded in 2018 by Michael S. Kim, an investor with over 30 years of experience in investment banking and principal investing. Kim’s background includes roles at Merrill Lynch and Morgan Stanley, and he leverages his extensive network of institutional investors, corporations, and sovereign wealth funds to support portfolio companies. The firm has evolved to focus sharply on biotech and deep tech sectors, emphasizing partnerships with founders to accelerate growth and technological development. Key partners include Michael Kim and Josh (last name not specified), who brings expertise in fund formation and cross-border finance, particularly in Asia[2][5][6].
These factors combine to create a venture capital firm that not only provides capital but also deep operational and strategic support to its portfolio companies[1][5][6].
In the broader tech landscape, Octave Ventures rides the wave of increasing convergence between deep technology and biotechnology, sectors driven by rapid scientific advances and growing market demand for innovative healthcare and industrial solutions. The timing is favorable due to accelerating breakthroughs in areas like molecular medicine, diagnostics, AI-driven biotech, and advanced materials. Market forces such as rising global healthcare needs, digital transformation, and increased public and private funding in science and technology create a fertile environment for Octave’s investments. By backing companies at the forefront of these trends, Octave influences the ecosystem by enabling technologies that can redefine industries and improve human health[1][3][6].
Looking ahead, Octave Ventures is poised to deepen its impact by continuing to invest in transformative biotech and deep tech startups approaching IPO readiness. Trends such as AI integration in biotech, personalized medicine, and sustainable technologies will likely shape their portfolio focus. Their influence may grow as they help bridge the gap between early innovation and public market success, fostering a new generation of tech-driven companies with global reach. This trajectory aligns with their mission to support breakthrough technologies that deliver outsized returns and societal benefits, reinforcing their role as a key player in the venture capital landscape for deep tech and biotech[3][5].
In summary, Octave Ventures stands out as a specialized VC firm that combines deep sector expertise, a strong network, and hands-on support to accelerate the growth of pre-IPO biotech and deep tech companies, positioning itself at the nexus of innovation and market transformation.
Octave has raised $187.0M across 6 funding rounds. Most recently, it raised $36.0M Series C in September 2025.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Apr 2, 2020 | Notion | $50.0M Series B | — | Bossa Invest, Goldman Sachs, ICONIQ Growth, Index Ventures, TGM ventures, Verdure Capital Management, Sam Altman |
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2025 | $36.0M Series C | Asset Management Ventures, Deerfield Management, Health Velocity Capital, Northpond Ventures, Section 32 | |
| Jul 1, 2023 | $33.0M Series B | Asset Management Ventures, Deerfield Management, Flare Capital Partners, Health Velocity Capital, Northpond Ventures, Optum Ventures, Section 32 | |
| Jun 1, 2023 | $52.0M Series C | American Express Ventures, Bessemer Venture Partners, Health Velocity Capital, sequel | |
| May 1, 2021 | $20.0M Series B | American Express Ventures, Bessemer Venture Partners, Health Velocity Capital, sequel | |
| Dec 1, 2020 | $32.0M Series B | Asset Management Ventures, Deerfield Management, Flare Capital Partners, Health Velocity Capital, Northpond Ventures, Optum Ventures, Section 32 | |
| Jul 1, 2018 | $14.0M Series A | Deerfield Management, Health Velocity Capital, Northpond Ventures, Section 32 |
